OBJECTIVES The goal of this study was to illustrate the potential benefit of effective congestive heart failure (CHF) treatment in terms of improved health, greater social value, and reduced health disparities between black and white subpopulations.
1.1 million disability-free life years, and 2.1 million quality-adjusted life years worth $210 to $420 billion. These gains are greater among black subjects than among white subjects.
CONCLUSIONS CHF prevalence will increase substantially over the next 2 decades and will affect black Americans more than white Americans. Improved CHF treatment could generate significant social value and reduce existing health T here is much concern about the increasing share of national income devoted to health care (1), but spending increases have been accompanied by significant health improvements.
Most significantly, age-standardized death rates from all causes have fallen 43% since 1969 (from 1,279 deaths per 100,000 in 1969 to 730 per 100,000 in 2013) (2). Better cardiovascular outcomes have driven much of this improvement, with age-adjusted deaths from heart disease falling from 520 per 100,000 in 1969 to 168.5 per 100,000 in 2015 (2,3). Evidence-based treatment of associated risk factors has been credited with contributing to these declines (4).
However, progress may be slowing and, in some disease areas such as congestive heart failure (CHF), may even be reversing. Medical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
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contributing factor in 1 in 9 U.S. deaths (4).
The Centers for Disease Control and Prevention reports that between 2011 and 2014, ageadjusted death rates from heart failure rose from 16.9 to 18.6 per 100,000 (5).
This trend may also exacerbate existing racial health disparities. African-American subjects develop heart failure earlier than white subjects and are more likely to be admitted to the hospital for this disease (6,7).
In addition, the 5-year risk-adjusted all-cause mortality rate for patients with CHF is 34%
higher for African-American subjects than for white subjects (8,9). Given these existing racial disparities, the fact that the ageadjusted death rates from CHF are increasing is particularly alarming.
Adding to the personal toll of CHF (premature death, disability, and loss of quality of life), its economic costs are substantial: almost $32 billion annually for U.S. treatment costs and lost productivity (7). Fortunately, recent treatment innovations suggest that the future impact of CHF on patient outcomes, economic productivity, and overall social value could be reduced, perhaps even in a way that mitigates health disparities (10-12).
The goal of the present paper was to model the potential benefits to population health from continued innovation in CHF treatment. Using U.S.
population-wide simulations, we estimated trends in CHF prevalence and how much improved CHF treatments could improve overall social value, as well as reduce racial and sex differences in health outcomes.
METHODS
To illustrate the potential benefits of improved CHF treatment, we adapted the Future Elderly Model Value of Heart Failure Treatment Innovation -2 0 1 8 : ---
